By Matt Skoufalos
Rick Neufarth has joined the business development team at the InterMed Group of Alachua, Florida. Neufarth has spent 20 years in sales and management, working in radiology, asset management, equipment sales and IDN partnerships for GE Healthcare and Siemens Healthcare.
EMD Serono of Rockland, Massachusetts has named John Walsh its vice president of neurology and immunology, U.S. medical affairs. Walsh was most recently senior director of U.S. medical, neurology medical director lead, at Biogen. A board-certified physician, Walsh has been a national disaster medical assistance team medical officer for the U.S. Department of Health & Human Services for seven years.
Syapse of San Francisco, California has added Dr. Aradhana Ghosh as vice president of oncology. A board-certified medical oncologist who has practiced hematology-oncology at Kaiser Permanente, Ghosh was medical director of specialty care for Santa Clara Health & Hospital System, has been as a physician executive at McKesson, focusing on medical informatics, and most recently was a medical oncologist at IBM Watson Health.
Dr. Aradhana Ghosh
Landmark Health of Huntingdon Beach, California has named Christopher Goldsmith its president. Goldsmith most recently was senior vice president of Envision Physician Services, has been senior vice president of national practice operations in Optum’s local care delivery business, and holds a bachelor’s degree in engineering from Duke University and an MBA from INSEAD.
TapImmune Inc. of Jacksonville, Florida has named Richard Kenney its acting chief medical officer. Kenney has been head of clinical development for TapImmune since May 2017, and also serves as president of ClinReg Biologics LLC.
Goldfinch Bio of Cambridge, Massachusetts has named Anthony Johnson its president and CEO and Michael Broxson its chief business and operating officer. Johnson was head of early clinical development for the Innovative Medicines and Early Development Biotech Unit at AstraZeneca, has been a venture partner at OrbiMed Advisors, and held R&D leadership roles at Bristol-Myers Squibb (BMS) and GlaxoSmithKline. Broxson spent 16 years at Takeda Pharmaceuticals, most recently as vice president and head of R&D business development. Interim CEO Abbie Celniker and interim COO Neil Exter, both partners at Third Rock Ventures, will remain on the Goldfinch Bio board of directors.
AAC Holdings Inc. of Brentwood, Tennessee has named Michael Nanko its president and COO, effective January 2018. Nanko has been president of behavioral health services for HCA Inc. since July 2016.
The Baim Institute for Clinical Research of Boston, Massachusetts named C. Michael Gibson its president and CEO. A cardiologist, researcher and educator, Gibson succeeds the retiring J. Spencer Goldsmith.
Aevi Genomic Medicine Inc. of Philadelphia, Pennsylvania added Matthew D. Bayley to its Board of Directors. Bayley is an senior vice president and chief strategy officer at the Children’s Hospital of Philadelphia and formerly was a partner at McKinsey & Company. Bayley holds an M.D. and an MBA from the University of Pennsylvania.
Medisafe of Boston, Massachusetts has named Henry Ancona chairman of the board. Ancona chairs the board at Signiant, and serves on the boards of BlueConic and Verne Global. He holds an MBA from Harvard Business School and bachelor’s and master’s degrees from MIT.
Outpost Medicine of Indianapolis, Indiana named Ian Mills its chief medical officer. Mills was head of clinical development for Mitsubishi Tanabe Pharma Europe, and spent more than 15 years in clinical and development leadership roles at Pfizer. He holds degrees from Cambridge and Oxford Universities.